Donor–host tissue interaction in allogenic transplanted tooth germ with special reference to periodontal tissue
ConclusionsThe current tooth germ transplantation suggests that the PDL contains putative stem cells, which never proliferate during E15–17, and is composed of resident dental follicle-derived cells and other cell population.
In conclusion, DPSCs are a potential source of stem cells in the field of eye stem cell therapy due to its protective effects against retinal degeneration.
Conclusion: This study found that there were no significant differences in QoL or level of depression between HSCT survivors and their spouse caregivers. Family income, gender, and co-morbidities showed significant association with spouse caregiver distress. PMID: 31309093 [PubMed]
Conclusion: Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. Further studies are required to assess its safety and efficacy at reduced doses. PMID: 31309088 [PubMed]
Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient; Donor; Hematopoietic and Lymphoid Cell Neoplasm Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Bendamustine; Drug: Bendamustine Hydrochloride; Drug: Cyclophosphamide; Biological: Filgrastim-sndz; Drug: Fludarabine; Drug: Fludarabine Phosphate; Drug: Melphalan; Drug: Mycophenolate Mofeti l; Biological: Rituximab; Drug: Tacrolimus; Ra...
Authors: Didier K, Robbins A, Antonicelli F, Pham BN, Giusti D, Servettaz A Abstract Systemic sclerosis is a rare connective tissue disease characterized by skin and several internal organ fibrosis, systemic vasculopathy and immune abnormalities. Even if fibroblasts and endothelial cells dysfunction, as well as lymphocytes and other immune cells implication are now well described, the exact origin and chronology of the disease pathogenesis remain unclear. Oxidative stress, influenced by genetic and environmental factors, seems to play a key role. Indeed, it seems to be implicated in the early phases of fibrosis dev...
CMV infection and CMV disease after allogeneic stem cell transplantation (allo-SCT) are associated with significant morbidity. Since the introduction of pre-emptive anti-CMV therapy for CMV-seropositive recipients, the incidence of CMV disease during the first year after allo-SCT has decreased from approximately 35% to 8 –10% . Well-known risk factors associated with CMV disease include CMV seropositivity, development of graft versus host disease (GvHD), prednisone treatment, and depletion of T cells from the graft.
Allogeneic hematopoietic stem cell transplant (HSCT) is increasingly used to treat both malignant and non-malignant conditions. Allogeneic HSCT is associated with a 30-70% incidence of graft-versus-host disease (GVHD), causing significant morbidity and mortality for these patients.1 Vulvovaginal GVHD was first described in adult women, and is thought to be a subtype of chronic GVHD based largely on the histologic appearance of the affected tissue.2, 3 The incidence of vulvovaginal GVHD has been reported to be 3-49%, but the true incidence is unknown and is thought to be severely underestimated.
Condition: Lymphoma, Large B-Cell, Diffuse Intervention: Drug: gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab Sponsor: Sun Yat-sen University Not yet recruiting
Abstract Epithelia are under constant threat from environmental carcinogens and none more so than squamous epithelia, which form the outermost linings of our bodies. Hence malignancies of squamous epithelia are collectively the most common cancer type and with the highest mortality, despite a constant cell turnover and only relatively rare long-lived adult tissue stem cells. Genetic analysis from SCC whole genome sequencing reveals commonality in mutated genes, despite various etiological factors. Most SCC types have been shown to exhibit hierarchical growth, in which a high frequency of cancer stem cells is assoc...
ConclusionOn the basis of our findings, we stress the importance of providers helping patients weigh the respective benefits and outcomes of AHSCT and non-AHSCT treatment approaches during the clinical encounter, a key tenet of shared decision-making.